A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity

被引：1
|
作者：
Cohen, S. J.
Zalupski, M. M.
Modiano, M. R.
Conkling, P. R.
Patt, Y. Z.
Davis, P.
Dorr, R. T.
Boytim, M. L.
Hersh, E. M.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Arizona Oncol Associates, Tucson, AZ USA
[4] Virgina Oncol Associates, Norfolk, VA USA
[5] Univ New Mexico, Albuquerque, NM 87131 USA
[6] Univ Arizona, Tucson, AZ USA
[7] Amplimed Corp, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.4619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4619
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer
    Kozloff, Mark
    Chuang, Ellen
    Roy, Jessica
    Starr, Alexander
    Gowland, Patricia A.
    Tarpey, Matthew J.
    Collier, Mary
    Verkh, Lev
    Kern, Kenneth
    Miller, Kathy
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3591S - 3591S
  • [32] Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: Preliminary results of a phase I study
    Lhomme, C
    Kerbrat, P
    Lejeune, C
    Guastalla, JP
    Fumoleau, P
    Goupil, A
    Heron, JF
    Cassin, MA
    Pruvot, I
    Soares, JA
    Chazard, M
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 48 - 54
  • [33] Phase I study of docetaxel, oxaliplatin, and capecitabine as first-line therapy to patients with advanced gastroesophageal cancer
    Schonnemann, K. R.
    Andersen, M.
    Yilmaz, M.
    Jensen, H. A.
    Vestermark, L. W.
    Pfeiffer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Clinical benefit with gemcitabine (GEM) as first-line therapy for patients with advanced pancreatic cancer (APC)
    Manzano, H
    Esquerdo, G
    Rifa, J
    Aguiar, D
    Arrivi, A
    Pazo, R
    Martin, J
    Terrasa, J
    ANNALS OF ONCOLOGY, 1998, 9 : 54 - 54
  • [35] Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced NonSmall Cell Lung Cancer
    Zhao, H.
    Zhang, Z.
    Li, S.
    Fang, W.
    Ma, Y.
    Zhang, Y.
    Yang, Y.
    Luo, F.
    Huang, Y.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S506 - S506
  • [36] Phase I trial of enzalutamide, gemcitabine, and nab-paclitaxel as a first-line treatment for advanced pancreatic cancer.
    Mahipal, Amit
    Springett, Gregory M.
    Burke, Nancy
    Neuger, Anthony
    Almhanna, Khaldoun
    Wapinsky, Georgine
    Bertels, Barbara
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study
    Tay, S. K.
    Ilanchadran, A.
    Tan, T. Y.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2006, 113 (12) : 1388 - 1392
  • [38] Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
    Lorusso, V
    Carpagnano, F
    Frasci, G
    Panza, N
    Di Rienzo, G
    Cisternino, ML
    Napoli, G
    Orlando, S
    Cinieri, S
    Brunetti, C
    Palazzo, S
    De Lena, M
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 405 - 411
  • [39] Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
    Colucci, Giuseppe
    Labianca, Roberto
    Di Costanzo, Francesco
    Gebbia, Vittorio
    Carteni, Giacomo
    Massidda, Bruno
    Dapretto, Elisa
    Manzione, Luigi
    Piazza, Elena
    Sannicolo, Mirella
    Ciaparrone, Marco
    Cavanna, Luigi
    Giuliani, Francesco
    Maiello, Evaristo
    Testa, Antonio
    Pederzoli, Paolo
    Falconi, Massimo
    Gallo, Ciro
    Di Maio, Massimo
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) : 1645 - 1651
  • [40] Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
    R Plummer
    P Lorigan
    E Brown
    R Zaucha
    V Moiseyenko
    L Demidov
    V Soriano
    E Chmielowska
    R Andrés
    G Kudryavtseva
    C Kahatt
    S Szyldergemajn
    S Extremera
    B de Miguel
    M Cullell-Young
    H Calvert
    British Journal of Cancer, 2013, 109 : 1451 - 1459
12345